Clinical Trial Update: A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018) [Phase 3]

View source ↗

Summary

Phase III trial evaluating safety and immunogenicity of Pneumovax 23 (V110) in participants from the Russian population has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-09-05